EMA Withdrawn: Kromeya (adalimumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

EMA has withdrawn Kromeya (adalimumab) from Fresenius Kabi Deutschland GmbH, effective 2019, affecting multiple inflammatory diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Arthritis Juvenile Rheumatoid
• Arthritis Psoriatic
• Arthritis Rheumatoid
• Colitis Ulcerative
• Crohn Disease
• Psoriasis
• Spondylitis Ankylosing
• Uveitis

Drugs mentioned

• Kromeya (adalimumab)

Snippet

Status: Withdrawn. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Juvenile Rheumatoid;Psoriasis;Arthritis, Psoriatic;Spondylitis, Ankylosing;Uveitis;Colitis, Ulcerative;Crohn Disease. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 03/10/2019